Low UBA7 gene expression was associated with poor survival as seen in CLL patients harboring SF3B1 mutations, suggesting its potential use as a biomarker for adverse prognostic outcomes. This evidence concerns the gene UBA7 and B-cell chronic lymphocytic leukemia.